Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Results round-up: Positive quarters for BD, HeartWare, Integra

This article was originally published in Clinica

Executive Summary

Becton Dickinson’s Q2 adjusted earnings of $1.53 per share grew 10% year-on-year and beat analyst predictions by $0.03. The firm was helped by “better profitability and a lower tax rate [that] more than offset slightly weaker revenue growth due to currency,” noted Jefferies analyst Brandon Couillard. The firm’s sales increased 4% year-on-year to $2.07bn, or 5% on a constant currency basis. However, its diagnostics division was “surprisingly weak,” with revenues down 1% (or +1% at constant exchange rates). This was offset by 5% and 8% growth in BD’s medical and biosciences units, respectively. Overall, the results “should inspire confidence in the prospects of a restoration of a double-digit growth trajectory in FY15, which should pique incremental investor attention,” concluded Mr Couillard. BD’s stock closed down 1% on 1 May, the day it reported the results, but its share price was up over 1% as Clinica went to press.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT101552

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel